Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
8
×
biotech
boston blog main
boston top stories
life sciences
national
national blog main
national top stories
pfizer
8
×
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
novartis
astrazeneca
cancer
clinical trials
amgen
bristol-myers squibb
eli lilly
johnson & johnson
merck
president trump
startups
What
bio
drug
roundup
acquisitions
annual
biggest
biotech
blood
ceo
company
conference
fda
news
prices
seven
today
week
albert
alzheimer’s
american
approved
ash
assessed
attention
august
away
borne
bourla
bringing
broader
build
busy
buy
cancer
cancers
ceos
communities
companies
company’s
crispr
Language
unset
unknown
Current search:
pfizer
×
abbvie
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More